Breast cancer prevalence in France

Breast cancer remains the most common cancer in women in France, with over 61,000 new cases diagnosed each year. The median age of diagnosis is 64, and more than 80% of tumors occur after the age of 40.

Early detection and survival rates

If detected early, breast cancer has a favorable prognosis, with a five-year survival rate of 88%, according to the National Cancer Institute. The institute describes the disease as resulting from "a disruption of certain cells that multiply and often form a mass," the tumor.

Advancements in treatment and de-escalation

Medical professionals are now focusing on "de-escalation" — reducing the intensity of treatment while maintaining effectiveness. Professor Khalil Zaman notes that between 60 and 70% of patients no longer need a mastectomy, with only the tumor area removed. Dr. Alfred Fitoussi adds that oncoplasty has preserved the nipple and areola for five to eight years.

Innovations in reconstructive surgery

Techniques like lipomodeling, which involves removing fat from other parts of the body and reinjecting it to reconstruct the breast, have gained momentum. This method provides a soft, warm, and mobile breast, closer in consistency and shape to the original. In contrast, traditional prostheses do not offer the same results.

Biodegradable prostheses in development

Research in reconstructive surgery is exploring biodegradable prostheses, such as those being developed by the French startup Lattice Medical. Their hollow prosthesis acts as a mold for the patient's own fatty tissues, dissolving as the tissues develop. This could revolutionize breast reconstruction.

Personalized treatment through tumor mapping

Mapping tumors involves analyzing cancer cells' genetic material and mutations to refine knowledge about different types of tumors. Dr. Fitoussi explains that this allows for almost personalized treatment plans, determining which therapy will be most effective for individual patients.

Advances in radiotherapy

Radiotherapy has seen progress in shorter treatment durations. Previously, patients underwent five to six weeks of treatment, but now it is often reduced to about three weeks. Studies show that higher doses over a shorter period do not increase side effects.

Hormone-sensitive cancers and therapy

Approximately 60% to 70% of breast cancers are hormone-sensitive, meaning estrogen can act as a growth factor for cancer cells. Hormone therapy aims to reduce recurrence risk by blocking hormones, and nearly three-quarters of patients receive this treatment for five to ten years.

CDK4/6 inhibitors and treatment progress

A study in ScienceDirect examined CDK4/6 inhibitors, which, when combined with hormone therapy, can double progression-free survival in some patients. These drugs have been available in France since 2018.

Importance of screening during Pink October

Health professionals emphasize the importance of screening during Pink October. About 60% of breast cancers are detected early, increasing recovery chances. Annual check-ups and mammograms are recommended for women aged 50 to 74.

Smart bra technology for early detection

Several biotech companies are developing smart bra solutions that use ultrasonic transducers to detect early cancerous areas. A Swiss startup is testing a "SmartBra" that emits ultrasonic waves to create 3D images of the breast, while MIT researchers have developed a similar ultrasound system integrated into a bra.

Lifestyle factors and cancer risk

Daily prevention includes reducing alcohol consumption, smoking, and overweight, as these are risk factors. A recent study found that replacing conventional fruits and vegetables with organic equivalents may reduce post-menopausal breast cancer risk. Reducing red meat intake also lowers cancer risk, and research is ongoing about the impact of anti-obesity drugs like GLP-1 on cancer prevention.

Hope for the future of breast cancer treatment

Alfred Fitoussi emphasizes the growing number of treatments tailored to individual cases, allowing patients to prolong their lives. Even those with metastases can now live several additional years thanks to targeted therapies, offering hope for the future.